305 related articles for article (PubMed ID: 32804301)
1. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition.
Shah P; Chavda K; Vyas B; Patel S
Drug Deliv Transl Res; 2021 Jun; 11(3):1166-1185. PubMed ID: 32804301
[TBL] [Abstract][Full Text] [Related]
2. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles.
Garg A; Bhalala K; Tomar DS; Wahajuddin
Int J Pharm; 2017 Jan; 516(1-2):120-130. PubMed ID: 27989820
[TBL] [Abstract][Full Text] [Related]
3. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
Alhamhoom Y; Ravi G; Osmani RAM; Hani U; Prakash GM
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364338
[No Abstract] [Full Text] [Related]
4. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
Patel MH; Mundada VP; Sawant KK
Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
[No Abstract] [Full Text] [Related]
5. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
7. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
10. Enhanced intestinal absorption of asenapine maleate by fabricating solid lipid nanoparticles using TPGS: elucidation of transport mechanism, permeability across Caco-2 cell line and in vivo pharmacokinetic studies.
Patel M; Mundada V; Sawant K
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):144-153. PubMed ID: 30669881
[TBL] [Abstract][Full Text] [Related]
11. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU
Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles.
Varshosaz J; Minayian M; Moazen E
J Liposome Res; 2010 Jun; 20(2):115-23. PubMed ID: 19694503
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
Dudhipala N; Veerabrahma K
Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
[TBL] [Abstract][Full Text] [Related]
14. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
15. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles.
Silki ; Sinha VR
AAPS PharmSciTech; 2018 Apr; 19(3):1264-1273. PubMed ID: 29313261
[TBL] [Abstract][Full Text] [Related]
17. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Thirupathi G; Swetha E; Narendar D
Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
[TBL] [Abstract][Full Text] [Related]
18. Improved uptake and bioavailability of cinnamaldehyde
Wu L; Meng Y; Xu Y; Chu X
Pharm Dev Technol; 2022 Dec; 27(10):1038-1048. PubMed ID: 36367964
[TBL] [Abstract][Full Text] [Related]
19. Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.
Nazief AM; Hassaan PS; Khalifa HM; Sokar MS; El-Kamel AH
Int J Nanomedicine; 2020; 15():1129-1148. PubMed ID: 32110012
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
